Why Intellia Therapeutics, Inc. (NTLA) Stock Dove Today. Lloyd Martinez-November 21, 2019. 0. Stock News. Here’s Why Intellia Therapeutics, Inc. (NTLA) Stock Rose Should You Buy Lineage Cell Therapeutics, Inc. (LCTX)’s Stock Price That’s December 30, 2019 Why Mereo BioPharma Group plc (MREO) Is An Unattractive Stock Today Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates. by Zacks Equity Research Published on August 01,2018 . Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.77% and 20.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock? NTLA